The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s MHRA, allowing the single-dose vaccine to be made ...

The development of polyvalent immunoglobulins purified from human plasma samples of convalescent Chikungunya patients could benefit infected viremic mothers and newborns.

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

Health officials have identified a group of patients showing symptoms of Chikungunya, including children and elderly ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

At least five suspected cases of chikungunya were recorded in Davao City in January 2025. The residents who were suspected of ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...